SERDs in Focus: Optimizing Treatment Strategies in HR+ HER2- Breast Cancer - Episode 1

Shifting Paradigms: Biomarker Testing and ESR1 Mutation Surveillance in HR+ HER2- Breast Cancer

January 15, 2025

Katherine Clifton, MD, Shipra Gandhi, MD

Dr. Clifton and Dr. Gandhi discuss the critical role of biomarker testing, particularly ESR1 mutation surveillance, in HR+/HER2- breast cancer, and its impact on prognosis and treatment decision-making.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

Now Viewing

EP. 1: Shifting Paradigms: Biomarker Testing and ESR1 Mutation Surveillance in HR+ HER2- Breast Cancer

EP. 2: Endocrine Sensitivity and the Prognostic and Clinical Implications

EP. 3: Approved and Investigational SERDs in HR+/HER2– Breast Cancer

EP. 4: Imlunestrant Clinical Data: Insights From the EMBER and EMBER-3 Trials

EP. 5: Translating Data With Oral SERDs to Practice: EMBER-3, SERENA-2, and Ongoing Trials

EP. 6: Insights From SABCS 2024 and Future Directions in Breast Cancer

Video content above is prompted by the following:

Please discuss the role of biomarker testing, particularly ESR1 mutation surveillance, in HR+/HER2- breast cancer.
How do the results of these tests influence prognosis and treatment decision-making?